环磷酰胺联合人免疫球蛋白治疗SLE 的临床疗效及对血清IL-4 及MCP-4 水平的影响

目的:探讨环磷酰胺联合人免疫球蛋白治疗系统性红斑狼疮的临床疗效及对血清白细胞介素-4(IL-4)及单核细胞趋化蛋白4(MCP-4)水平的影响。方法:选取我院2013年1月到2014年5月收治的76例系统性红斑狼疮患者进行研究,随机分为观察组和对照组各38例。对照组使用环磷酰胺联合强的松的治疗,观察组采用人免疫球蛋白、环磷酰胺及强的松联合治疗,应用系统性红斑狼疮疾病活动度评分(SLEDAI)评价疾病程度,记录治疗前后两组24h尿蛋白、血清IL-4及MCP-4水平,并观察不良反应发生率。结果:治疗后两组SLEDAI评分、24h尿蛋白及血清IL-4及MCP-4水平较治疗前均显著降低(P0.05),且观察组均显著低于对照组(P0.05)。观察组不良反应发生率显著低于对照组(P0.05)。结论:环磷酰胺联合人免疫球蛋白治疗系统性红斑狼疮的效果显著,有效降低了患者血清IL-4及MCP-4的水平,对患者的预后有积极的影响。

Clinical Effect of Cyclophosphamide Plus Human Immunoglobulin forSystemic Lupus Erythematosus

Objective:To explore the clinical effect of cyclophosphamide plus human immunoglobulin in treatment of systemiclupus erythematosus(SLE) and its impact on serum interleukin-4(IL-4) and monocyte chemoattractant protein 4(MCP-4) levels.Methods:A total of 76 patients with SLE, who were admitted to Shifang People''s Hospital from January 2013 to May 2014, were chosen as the researchsubjects and randomly divided into observation group (n=38) and control group (n=38). The control group was treated with cyclophosphamidecombined with prednisone, while the observation group was added human immunoglobulin on the basis of controlgroup''s therapy. The extent of the disease was evaluated by systemic lupus erythematosus disease activity score (SLEDAI). The levels of24h urine protein, serumIL-4 and MCP-4 in the two groups before and after treatment were recorded, and the adverse reactions were observed.Results:Compared with before treatment, SLEDAI scores, 24 h urine protein and serumIL-4, MCP-4 levels in the two groups aftertreatment significantly decreased (P<0.05), and the above indexes in the observation group were lower than those in the control group(P<0.05). The adverse reaction in the observation group was significantly lower than that in the control group (P<0.05).Conclusion:Cyclophosphamideplus human immunoglobulin has a remarkable effect in the treatment of patients with SLE, which can effectively cutdown the serumMCP-4 and IL-4 levels and has a positive impact on the prognosis of the patients with SLE.